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Immune Modulation by Group B Streptococcus Influences Host
Susceptibility to Urinary Tract Infection by Uropathogenic Escherichia
coli
Kimberly A. Kline,* Drew J. Schwartz, Nicole M. Gilbert, Scott J. Hultgren, and Amanda L. Lewis
Department of Molecular Microbiology, Center for Women’s Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri, USA
Urinary tract infection (UTI) is most often caused by uropathogenic Escherichia coli (UPEC). UPEC inoculation into the female
urinary tract (UT) can occur through physical activities that expose the UT to an inherently polymicrobial periurethral, vaginal,
or gastrointestinal flora. We report that a common urogenital inhabitant and opportunistic pathogen, group B Streptococcus
(GBS), when present at the time of UPEC exposure, undergoes rapid UPEC-dependent exclusion from the murine urinary tract,
yet it influences acute UPEC-host interactions and alters host susceptibility to persistent outcomes of bladder and kidney infec-
tion. GBS presence results in increased UPEC titers in the bladder lumen during acute infection and reduced inflammatory re-
sponses of murine macrophages to live UPEC or purified lipopolysaccharide (LPS), phenotypes that require GBSmimicry of
host sialic acid residues. Taken together, these studies suggest that despite low titers, the presence of GBS at the time of polymi-
crobial UT exposure may be an overlooked risk factor for chronic pyelonephritis and recurrent UTI in susceptible groups, even if
it is outcompeted and thus absent by the time of diagnosis.
Urinary tract infection (UTI) is one of the most common bac-terial infections in humans, occurs mostly in women, and is
most often caused by uropathogenic Escherichia coli (UPEC). Ap-
proximately 8million outpatient visits occur each year due toUTI,
causing an estimated $2 billion in annual health care costs in the
United States (15). It is commonly held that the urinary tract (UT)
and its contents are sterile in the absence of overt UTI. However,
many reports strongly suggest that the female UT is routinely ex-
posed to a diversity of microbes, translocated by physical activity
such as sexual intercourse from the nearby periurethral, vaginal,
or rectal flora (8, 21, 61). We reason that the diversity and abun-
dance of microbes present in rectovaginal and periurethral “stag-
ing areas” (2, 10, 14, 49) likely result in bacterial exposures of the
UT that are polymicrobial in nature. Despite this, experimental
studies have not been performed to examine whether common
host carrier states (commensals or potential pathogens of the fe-
male urogenital tract) alter the host-pathogen equation when
present together in a polymicrobial UT exposure.
UPEC is the most common cause of UTI and has been exten-
sively studied using murine models of transurethral inoculation.
Colonization of the urinary tract triggers early innate host re-
sponses involving both hematopoietic and stromal cells that func-
tion in mediating the clearance of acute UPEC infection (19, 53,
54). These acute responses to UPEC rely on the induction of local
and systemic chemokines and cytokines, exfoliation of epithelial
barriers, and infiltration of innate immune cells such as neutro-
phils and monocytes (18, 43). UPEC employs a number of viru-
lencemechanisms in order to subvert these innate defenses, which
enables the pathogen to persist and cause disease (18).
Adhesive pili assembled by the chaperone/usher pathway, such
as type 1 pili, contain adhesins at their tips that are thought to play
an important role in host-pathogen interactions. The mannose-
binding type I pilus tip adhesin FimHmediates UPEC attachment
and invasion of bladder epithelial cells (30, 31, 66), and thus,
UPEC can be isolated from both luminal and gentamicin-pro-
tected intracellular compartments as early as 1 h postinfection
(hpi) (29). Within superficial bladder epithelial cells, UPEC can
replicate to form biofilm-like intracellular bacterial communities
(IBCs) (1). Escape of UPEC into the cytosol and subsequent IBC
formation may be a mechanism to subvert Toll-like receptor 4
(TLR4)-dependent expulsion of UPEC via an exocytic vesicle (3,
60). During IBCmaturation, UPEC organisms undergo morpho-
logical changes, disperse from the IBC biomass, and flux out of the
epithelium into the extracellular milieu, where they are capable of
invading new epithelial cells to begin the cycle anew (28).
Reflective of different disease manifestations in humans, ex-
perimental UPEC infection can result in various long-term se-
quelae. One distinct outcome is the formation of antibiotic-toler-
ant, quiescent intracellular reservoirs (QIRs) that form in the
bladder within 7 to 10 days during the resolution of bacteriuria in
acute infection. QIRs are distinct from IBCs that form during the
first 24 hpi, and they are comprised of fewer than 15 bacteria
persisting in a membrane-bound dormant state within transi-
tional epithelial cells. Resolution of bacteriuria and bladder titers
of less than 103 are reflective of QIR formation and have been
studied mainly in C57BL/6 mice, in which they can persist in the
bladder and are later able to seed new rounds of infection (40, 52).
An alternative outcome is the development of long-lasting,
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chronic cystitis characterized by persistent, high-titer bacteriuria
(104 CFU/ml), as well as high-titer bacterial bladder burdens at
sacrifice 4 weeks postinfection (wpi), chronic inflammation,
and urothelial necrosis. Severe pyuria and elevated levels of inter-
leukin 6 (IL-6), granulocyte colony-stimulating factor (G-CSF),
keritinocyte-derived chemokine (KC), and IL-5 in serum within
the first 24 hpi precede chronic infection in C3H/HeN mice and
are greater than 95% predictive of future development of chronic
UTI (17).
Despite a strong acute inflammatory response directed toward
UPEC, C3H/HeN mice not only are susceptible to acute cystitis
but also often develop high-titer chronic cystitis and chronic as-
cending pyelonephritis (17, 23). Recent studies show that elevated
systemic inflammatory cytokine responses are prognostic indica-
tors of chronic cystitis development by UPEC (17). In contrast,
the related C3H/HeJ mouse strain, which lacks functional TLR4
responses to Gram-negative lipopolysaccharide (LPS) (24, 47),
exhibits higher-titer cystitis and pyelonephritis than C3H/HeN
mice, without evidence of significant histological inflammation
(16, 19, 23, 54, 56). Taken together, these data provide a detailed
understanding of monomicrobial UPEC infection, particularly in
theC3H/HeNandC3H/HeJmouse backgrounds, althoughUPEC
pathogenesis and IBC formation have also been studied inC57BL/
6J, CBA/J, and FVB/NJ mice (13). We employed the C3H/HeN
and C3H/HeJ models to investigate whether the presence of a
common urogenital inhabitant and potential pathogen, group B
streptococcus (GBS), at the time of UPEC exposure can funda-
mentally alter the cellular or molecular dynamics of UPEC-host
interactions.
GBS is a Gram-positive bacterium that asymptomatically col-
onizes the lower gastrointestinal, vaginal, and/or urinary tract in
up to 65% of healthy women (38). While the bacterium has
evolved to coexist peacefully in most immunocompetent adults,
certain susceptible individuals, such as newborns, pregnant women,
and the elderly, are at higher risks of developing invasive GBS
infections (59, 70). GBS is best known as a leading cause of pneu-
monia, bacteremia, sepsis, and meningitis in newborns (5, 70). A
less recognized focus of infection for GBS is the UT. GBS causes
about 1% of all monomicrobial UTIs (approximately 80,000 an-
nually), which occur largely in immunocompromised, diabetic,
elderly, and pregnant populations (11, 65). We recently demon-
strated that GBS mediates both immune suppression and activa-
tion in a murine model of UTI (32). GBS uses sialic acid residues
of its capsular polysaccharide to suppress oxidative burst re-
sponses of murine polymorphonuclear cells (PMNs), and unnat-
urally high levels of sialic acid O-acetylation (OAchi strain) block
the ability of GBS to suppress PMNs compared to an isogenic
OAclo strain (32, 68). We further showed that GBS OAclo organ-
isms, which were capable of suppressing PMN oxidative burst,
survived better in the urinary tract of C3H/HeN mice than the
isogenic OAchi strain (32, 68). In this study, we investigated the
hypothesis thatGBSpresencewithin a polymicrobialUT exposure
may shape inflammatory processes that influence host-UPEC in-
teractions. We show that GBS can influence long-term outcomes
of UPEC UTI despite its own rapid elimination in the presence of
UPEC. Further, we present evidence that prior to its demise, GBS
employs sialic acid residues of its capsular polysaccharide to fun-
damentally alter the cellular dynamics of early UPEC-host inter-
actions.
MATERIALS AND METHODS
Bacterial strains andgrowth conditions.Wild-type (WT)uropathogenic
E. coli strain UTI89 (39), UTI89 attHK022::COM-GFP (kanamycin resis-
tant [Kanr]) (69), UTI89 FimH Q133K (SLC2-35-1) (6), and UTI89
FimHwild-type control strain (SLC2-33-1) (6) were inoculated from sin-
gle colonies grown on LB agar into LB broth, containing kanamycin at 25
g/ml where appropriate, and grown statically overnight (18 to 24 h) at
37°C. In the wild-type UPEC strains under investigation, these standardly
used growth conditions result in optimal expression of type 1 pili (6, 28),
necessary for establishing a urinary tract infection. Streptococcus agalactiae
(also called group B streptococcus [GBS]) wild-type strain COH1, a well-
characterized strain that expresses low levels of the -hemolysin and high
levels of the capsular polysaccharide, or isogenic mutants of GBS COH1
expressing sialic acids with minimal O-acetylation (OAclo) or hyper-O-
acetylation of sialic acids (OAchi) (34, 35, 67, 68) were used in these stud-
ies. As previously described, the WT COH1 strain has an intermediate
level of O-acetylation (67). For all experiments, GBS was inoculated from
single colonies grown on Todd-Hewitt (TH) agar into TH broth with
antibiotics where appropriate, grown statically overnight, and then di-
luted 1:10 in fresh TH broth for an additional 1 to 2 h at 37°C to an optical
density at 600 nm (OD600) of approximately 0.4 (logarithmic phase) as
previously described for GBS UTI and other in vivo virulence studies (9,
32, 68).
Murine infections. Bacterial cultures, grown as described above, were
collected by centrifugation and resuspended in phosphate-buffered saline
(PBS). Female wild-type mice, 7 to 10 weeks of age, were obtained from
Harlan (C3H/HeN) or the Jackson Laboratories (C3H/HeJ). Mice were
anesthetized by inhalation of 3% isoflurane. Mice were then voided prior
to transurethral bacterial inoculationwith 1 107 to 2 107CFU in 50l
(26). For mixed infections, GBS and UPEC were mixed to obtain a 50-l
bacterial suspension of 1  107 to 2  107 CFU of each organism. At
various time points, mice were euthanized and bladders and kidneys were
aseptically removed. The number of bacteria present in the tissues was
determined by homogenization of bladders or kidney pairs in PBS and
plating of serial dilutions on LB or TH agar. For coinfection studies, sam-
ples were plated on MacConkey agar and Columbia CNA agar plus 5%
sheep blood, supplemented with antibiotics when appropriate, to differ-
entiate between Gram-negative and Gram-positive bacteria, respectively.
Alternately, ex vivo gentamicin protection assays were performed on ex-
cised bladders to assess the extracellular and intracellular populations in
the bladder (29). Briefly, bladders were removed at 3 hpi, quadrisected to
assist in thoroughwashing of the tissue, andwashed 3 times in 500l fresh
PBS with gentle mixing. Enumeration of total CFU from the 3 pooled
washes indicates luminal or loosely attached extracellular bacteria. Gen-
tamicin treatment (100g/ml) proceeded at 37°C for 90min, followed by
thorough washing, homogenization, and enumeration of gentamicin-
protected bacteria. The supernatant from the gentamicin treatment was
plated separately on nonselective media to ensure that all extracellular
UPEC and/or GBS organisms were killed by the gentamicin during the
incubation. Statistical analyses were performed using the Mann-Whitney
test with GraphPad Prism software (version 5.00 forWindows; GraphPad
Software). Recovered titers of 0 are graphed at the limit of detection of the
assay, andmedian titers are indicated in all figures. All animal studies were
performed in accordance with the Committee for Animal Studies at
Washington University School of Medicine.
Cytokinemeasurement.UPEC, GBS, andUPEC plus GBS were inoc-
ulated into mouse bladders as described above, and venous blood was
collected at 24 hpi by submandibular puncture into 400-l Microtainer
serum separation tubes (BD). After coagulation, Microtainer tubes were
subjected to centrifugation at 15,000  g for 5 min at 4°C and stored at
20°C. Cytokine expression was measured using the Bio-Plex multiplex
cytokine bead kit (Bio-Rad), which measures 23 different proinflamma-
tory cytokines. Statistical analyses were performed in GraphPad Prism
using the Mann-Whitney U test.
GBS Alters UPEC UTI
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NF-B assays. RAW-Blue cells (murine RAW 264.7 macrophages
with chromosomal integration of a secreted embryonic alkaline phospha-
tase [SEAP] reporter construct inducible by NF-B; Invivogen) were
maintained in Dulbecco modified Eagle medium (DMEM), 4.5 g/liter
glucose, 2 to 4 mM L-glutamine, 10% (vol/vol) fetal bovine serum, 50
U/ml penicillin, 50 g/ml streptomycin, 100 g/ml Normocin, and 200
mg/ml Zeocin at 37°C in 5% CO2. For infection experiments, cells were
seeded into a 96-well plate (Falcon Microtest tissue culture plate, flat
bottom, low evaporation lid, catalog no. 35307; BD) at 100,000 cells/
well in 200l antibiotic-freemedium, according to the supplier’s instruc-
tions. After overnight incubation, cells were washed with PBS, and 180l
fresh medium was added. Wells (triplicate for each condition) were
treated with 20l LPS from E. coliO26:B6 at 10 ng/ml (catalog no. L2654;
Sigma), empirically determined for optimal SEAP activity in LPS dilution
series experiments. Cells were also infected with GBS, UPEC, or GBS plus
UPEC (at a 20:1, 10:1, or 1:1 ratio of bacteria to macrophage) in PBS or
PBS only as amock-infected control and incubated at 37°C in 5%CO2. At
6 hpi, 20l supernatant was removed and added to 180l QUANTI-Blue
(Invivogen), the mixture was incubated at 37°C overnight, and SEAP
levels were determined at 640 nm. Results shown depict one representa-
tive experiment of at least three biologically independent experiments
performed. Lactate dehydrogenase assays (Clontech) were performed ac-
cording to the manufacturer’s instructions on macrophage supernatants
after exposure to WT GBS for 6 h.
RESULTS
Bladder coexposure to GBS and UPEC alters host interactions
with both organisms. To investigate the impact of bacterial coin-
oculation on the early cellular dynamics of host-microbe interac-
tions in the bladder, we measured lumen- and tissue-associated
titers of GBS and UPEC following mono- and coinoculations. In
order to evaluate the number of bacteria that had invaded the
bladder tissue 3 h after transurethral exposure to bacteria (GBS,
UPEC, or coinoculated GBS and UPEC), an ex vivo gentamicin
protection assay was performed on each murine bladder (39).
Extracellular bacteria surviving in the bladder lumen were mea-
sured from tissue washes prior to gentamicin treatment, followed
by recovery and enumeration of gentamicin-protected, tissue-as-
sociated bacteria. In these experiments, extracellular UPEC CFU
were significantly elevated in the lumen at 3 hpi in the presence of
GBS compared to UPEC alone (Fig. 1A). The ability of UPEC to
invade the urothelium and enter gentamicin-protected intracellu-
lar compartments was not altered by the presence of GBS
(Fig. 1B). While UPEC presence led to an apparent reduction of
GBS fitness in the acutely coinfected bladder lumen, UPEC did
not affect the ability of GBS to occupy a gentamicin-protected
niche (Fig. 1B). This is, to our knowledge, the first report thatGBS,
like UPEC, can inhabit gentamicin-protected bladder tissue com-
partments in vivo. We obtained identical growth curves for GBS
and UPEC during mono- and coculture of the organisms in vitro,
strongly suggesting that host factors contribute to the observed
population dynamics in the bladder (Fig. 1C). These data show
that GBS accessesmultiple bladder niche environments within the
first few hours of coinfection and leads to increased fitness of
UPEC in the bladder lumen during acute infection.
GBS capsule sialic acids promote UPEC survival in the blad-
der lumen. Previous studies have shown that bladder epithelial
cells are capable of expelling invaded UPEC (60). Thus, increased
luminal titers of UPEC in the presence of GBS may involve intra-
cellular transit of UPEC followed by their expulsion into the lu-
men. The FimH::Q133K mutation, which abolishes the primary
mannose-dependent adhesive interaction of UPEC with bladder
epithelial cells (25), was used to investigate whether FimH-medi-
ated binding and invasion of the bladder tissue were required for
the enhanced early survival of UPEC in the presence of GBS.Mice
were mono- or coinfected with GBS and the FimH::Q133K mu-
tant of UPEC strain UTI89 (6). In monoinfected mice, UPEC
bearing the Q133K FimH mutation was unable to bind or invade
the bladder epithelium and was cleared from the bladders of most
animals by 3 hpi (Fig. 2A) (6). However, we discovered that in the
presence of GBS, UPEC bearing the Q133K FimH mutation sur-
vived significantly better in the acutely infected bladder lumen
(Fig. 2A). In contrast, the invasion of Q133K UPEC remained
defective even in the presence of GBS, as determined by gentami-
cin protection (Fig. 2A). GBS-mediated enhancement of UPEC
bearing FimH::Q133K was limited to acute infection and was not
observed at 24 hpi (data not shown). These results demonstrate
that FimH-mediated attachment and invasion by UPEC are not
required for GBS augmentation of UPEC survival in the bladder
lumen.
We recently showed that GBS capsular sialic acid residues sup-
FIG 1 GBS alters the cellular dynamics of UPEC-host interactions in the bladder. Gentamicin protection assays were performed on excised bladders of mono-
or coinoculated animals at 3 hpi. (A) Lumen titers were determined by bacterial enumeration of pooled washes of quadrisected bladder tissue and may include
bacteria loosely attached to the bladder tissue. (B) Gentamicin-resistant CFU associated with bladder tissue. n  5 or 6, at least 5 mice per experiment. The
horizontal bar represents the median value for each group of mice. Statistical significance was determined by the Mann-Whitney test. *, P	 0.05. The dashed
horizontal line indicates the limit of detection of the assay. Titers below the limit of detection were assigned a value of 1 for visualization on the log scale and 0
for statistical analyses. (C) Bacteria were grown in mono- or coculture in vitro, indicated by black or gray shapes, respectively. Error bars represent the standard
deviations of 3 technical replicates sampled at each time point.
Kline et al.
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press PMNoxidative burst responses and enhanceGBS survival in
the urinary tract of C3H/HeN mice (32, 68). To determine
whether GBS capsular sialic acids also play a role in the observed
GBS augmentation of UPEC survival, we analyzed intracellular
and extracellular UPEC survival in the presence of isogenic GBS
strains bearing high or low levels of sialic acidO-acetylation. Blad-
ders were removed 3 h after transurethral coinoculation, followed
by enumeration of luminal and intracellular GBS and UPEC or-
ganisms. While the lumen titers of GBS OAchi and OAclo strains
did not differ significantly at this early time point, wild-type lumi-
nal UPEC CFU were elevated in the presence of GBS OAclo com-
pared to GBSOAchi (Fig. 2B). There were no differences observed
in the intracellular UPEC or GBS populations under any of these
conditions. These results establish that GBS acts through a sialic
acid-mediated mechanism to enhance UPEC titers in the bladder
lumen.
GBS augmentation of UPEC in the bladder lumen occurs in
C3H/HeN but not C3H/HeJ mice. To further investigate the hy-
pothesis that GBS may suppress immune responses during acute
infection, we examined the fate of UPEC in mono- or coinfected
C3H/HeJ mice, which lack a functional TLR4 receptor and thus
are unable to mount a robust inflammatory response to UPEC
(16, 22, 53, 54). We reasoned that if GBS suppresses TLR4-medi-
ated inflammatory responses, UPEC should derive no significant
benefit from GBS in the bladder of C3H/HeJ coinfected mice,
since immune responses to UPEC in this host background are
already blunted. UPEC CFU in the bladder lumens of C3H/HeJ
and C3H/HeN mice were compared after coinfection with GBS.
Consistent with our hypothesis, C3H/HeJ mice (in contrast to
their C3H/HeN counterparts) did not exhibit a GBS-dependent
augmentation of UPEC titers in the bladder (Fig. 3A). Enumera-
tion of bacterial titers in the kidneys revealed a significant GBS-
dependent reduction of UPEC titers in C3H/HeJ mice compared
to C3H/HeN mice (Fig. 3B). These data further support the hy-
pothesis that GBS modulation of TLR4-dependent innate pro-
cesses is likely responsible for the observed augmentation of
UPEC in the acute bladder. Moreover, the data suggest that GBS
may have distinct effects on UPEC-host interactions in the blad-
der and kidneys for reasons that are currently unknown.However,
recent studies have shown that there is at least one additional
FIG 2 GBS capsule sialic acids enhance UPEC survival in the bladder lumen during acute infection. Gentamicin protection assays were performed on excised
bladders (3 hpi) of mono- or coinoculated animals. (A) Lumen bladder survival assays using the bladder binding-defective UPEC FimH::Q133K mutant in the
presence or absence of WT GBS. (B) Lumen bladder survival assays after coinoculation of WT UPEC and GBS capsule mutants. n  2, at least 5 mice per
experiment. The horizontal bar represents themedian value for each group ofmice. Statistical significance was determined by the two-tailedMann-Whitney test.
*, P	 0.05; **, P	 0.01; ***, P	 0.001. The dashed horizontal line indicates the limit of detection of the assay. Titers below the limit of detection were assigned
a value of 1 for visualization on the log scale and 0 for statistical analyses.
FIG 3 UPEC augmentation by GBS in the bladder lumen does not occur in C3H/HeJ mice. Gentamicin protection assays were performed on excised bladders
(A) and kidney CFU were determined (B) in mono- or coinoculated C3H/HeN and C3H/HeJ mice at 3 hpi. UPEC bladder CFU from C3H/HeN mouse data
shown here are replotted from Fig. 1A for ease of comparison with data obtained from C3H/HeJ mice. Metadata from 6 experiments are shown for C3H/HeN
mice; n 2 for C3H/HeJmice, with at least 5mice per experiment. The horizontal bar represents themedian value for each group ofmice. Statistical significance
was determined by the two-tailed Mann-Whitney test. *, P	 0.05. The dashed horizontal line indicates the limit of detection of the assay. Titers below the limit
of detection were assigned a value of 1 for visualization on the log scale and 0 for statistical analyses.
GBS Alters UPEC UTI
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genetic locus (in comparison to C3H/HeNmice) that contributes
to the well-known susceptibility of the C3H/HeJ strain to UTI
(62), and thus, further studies were carried out to investigate the
effect of GBS on TLR4-mediated processes.
NF-B-driven transcription by murine macrophages in re-
sponse to UPEC and LPS is suppressed by GBS in a sialic acid-
dependent manner. The hypothesis that GBS may suppress im-
mune responses specifically resulting fromLPS-TLR4 interactions
was investigated by measuring the ability of GBS to affect LPS- or
UPEC-driven activation of the transcription factor NF-B inmu-
rine macrophages. Macrophages encoding a stable secreted alka-
line phosphatase reporter downstream of NF-B-responsive pro-
moter sequences were exposed to different combinations and
doses ofUPEC, LPS, and/orGBS. As expected, strong induction of
NF-B-dependent transcription was observed in response to LPS
alone or UPEC alone at 6 hpi in control experiments (Fig. 4A and
B). In contrast, when GBS was added to macrophages together
with UPEC (Fig. 4A) or LPS (Fig. 4B), macrophages no longer
responded by upregulating NF-B-dependent transcription. Al-
though GBS has previously been shown to induce macrophage
apoptosis at a relatively high multiplicity of infection (MOI)
(100:1 ratio of bacteria tomacrophage) following 24 h of exposure
(12, 64), the lowerMOI (1:1, 1:10, or 1:20) and shorter duration (6
h) of these experiments with WT GBS did not result in macro-
phage death, as evidenced by the absence of lactate dehydrogenase
(27) in supernatants of macrophages exposed to WT GBS (data
not shown). These data demonstrate that the Gram-positive GBS
engages in suppression ofNF-B-drivenmacrophage responses to
Gram-negative LPS.
To determine if GBS capsule sialic acids participate in themod-
ulation of macrophage NF-B-driven responses, similar to their
contribution to suppression of PMN activity (32), we investigated
macrophage activationwithOAchi andOAclo strains of GBS in the
presence or absence of simultaneous LPS stimulation. In the ab-
sence of LPS stimulation, OAclo GBS suppressed NF-B-driven
proinflammatory responses in murine macrophages, while high
levels of sialic acid O-acetylation on the isogenic OAchi strain
blocked the ability ofGBS to suppressmacrophage activation (Fig.
4C). A similar phenotype was observed in the presence of LPS,
where OAclo GBS suppressed LPS-inducedNF-B-driven inflam-
mation, while OAchi GBS was unable to limit NF-B-driven mac-
rophage responses in the presence of LPS. This discovery adds
GBS to a growing number of pathogens that can inhibit NF-B
signaling as a pathogenic strategy (33, 42). Taken together with
evidence that capsule sialic acids also contribute to UPEC survival
in the bladder lumen (Fig. 2A), these data strongly implicate direct
immune modulation of TLR4-dependent processes by the GBS
capsule in alteration ofUPEC-host interactions following polymi-
crobial UT exposure.
GBS presence during acute UTI reduces the risk of chronic
high-titerUPEC cystitis but increases the risk of latent bacterial
reservoirs and the severity of ascending kidney infection. The
ramifications of GBS exposure on long-term UTI outcomes were
also investigated. Analysis of serum cytokines at 24 hpi was per-
formed to examine the possibility that GBS may shift the previ-
ously described checkpoint of host acute inflammatory responses
linked with the development of chronic cystitis (17). Mice were
inoculated with UPEC alone or coinoculated with GBS, followed
by analysis of serum cytokines at 24 hpi, urine CFU over the
course of infection, and bladder and kidney titers at 4 wpi. We
found that the inflammatory cytokine signature previously shown
to predict the development of chronic UPEC cystitis in monoin-
fected mice (IL-6, KC, and G-CSF) (17) also correlated with the
development of chronic infection following mixed inoculation
regardless of GBS dose (Fig. 5A to C); however, the proportion of
mice succumbing to chronic high-titer cystitis was affected (see
below). UPEC CFU in the bladder at 24 hpi, the time point at
which cytokines were analyzed, did not differ betweenmono- and
coinfected animals. In contrast, GBS had been preferentially
eliminated in the presence of UPEC from most animals by 24
hpi (Fig. 5D).
Examining the consequence of coinoculation on long-term in-
fections, we observed a unique dose-dependent effect of GBS on
the development of UPEC chronic high-titer cystitis (104
CFU/ml with bacteriuria), the presence of latent UPEC reservoirs
(	104 CFU/ml without bacteriuria), and the ability of UPEC to
cause high-titer infections of the kidney. When high-dose GBS
and UPEC (107 each) were coinoculated, significantly fewer
FIG 4 GBS suppresses macrophage NF-B-driven inflammation in response to LPS and UPEC. Murine macrophage RAW267.4 cell line expressing a stable
chromosomally integrated secreted embryonic alkaline phosphatase (SEAP) reporter downstream of 6 repeatedNF-B-responsive elements was stimulated with
UPEC,GBS, orUPECplusGBS (mixed bacterial inoculation) (A); LPS in the presence or absence ofGBS atMOIs of 1:1, 10:1, and 20:1 (B); or LPS in the presence
of GBS capsule mutants (MOI, 10:1) that are augmented (OAclo) or attenuated (OAchi) in GBS murine cystitis (C). Following 6 h of stimulation, NF-B-
dependent transcriptional activity was measured in cell supernatants (SEAP activity). Data shown reflect one representative experiment of at least 3 biologically
independent experiments performed. Each bar reflects data from 3 technical replicates. Statistical significance was determined by the unpaired two-tailed t test.
*, P	 0.05; **, P	 0.01; ***, P	 0.001.
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mice developed persistent bacteriuria (data not shown) and
chronic cystitis (104 CFU/ml) at 4 wpi compared to animals that
received monomicrobial inoculation of UPEC (Fig. 6A). Instead,
high-dose GBS shifted UPEC outcomes toward a lower-titer
(	104 CFU/ml) latent reservoir as previously described (22–24).
Coinfection with a slightly lower dose of GBS (approximately 2:1
ratio of UPEC to GBS) eliminated the GBS-dependent shift in
UPEC outcomes toward latent reservoirs, instead rendering the
animals more susceptible to high-titer chronic cystitis than with
high-dose GBS (Fig. 6A). Consistent with this finding, mice coin-
fected with the lower dose of GBS had significantly higher UPEC
titers in the bladder and kidneys at 4 wpi than with UPEC alone or
high-dose GBS (Fig. 6B and C). Together, these data demonstrate
that GBS presence within the first 24 h after mixed microbial ex-
FIG 5 GBS coinoculation induces cytokines associated with UPEC chronic cystitis in C3H/HeN mice. (A to C) Serum cytokine analysis at 24 hpi of C3H/HeN
mice mono- and coinoculated with107 UPEC UTI89 alone or coinoculated with 1 107 to 2 107 GBS COH1 CFU (high dose) or 2 106 to 9 106 GBS
COH1 CFU (low dose), stratified by animals that went on to develop chronic cystitis or that resolved infection (see Fig. 6). n 3, at least 5 mice per experiment.
(D) UPEC and GBS CFU in the bladder at 24 h after transurethral inoculation with 107 GBS COH1 organisms alone or coinoculated with 107 UPEC UTI89
organisms. n 4 experiments, with at least 5 mice per experiment. The horizontal bar represents the median value for each group of mice. The dashed horizontal line
indicates the limit of detection of the assay. Titers below the limit of detectionwere assigned a value of 1 for visualization on the log scale and 0 for statistical analyses. For
both serum cytokine levels and CFU, statistical significance was determined by the two-tailedMann-Whitney test. *, P	 0.05; **, P	 0.01; ***, P	 0.001.
FIG 6 GBS coinoculation has dose-dependent effects on the development of chronic UPEC cystitis and pyelonephritis C3H/HeN mice. (A) The percentage of
mice displaying104 CFU/bladder at 4 wpi, indicative of chronic cystitis following infection of C3H/HeN mice with107 UPEC UTI89 organisms alone, or
coinoculated with high-dose GBS (1 107 to 2 107 GBSCOH1CFU,1:1 ratio of UPEC toGBS) or low-dose GBS (2 106 to 9 106 GBSCOH1CFU,2:1
ratio of UPEC to GBS). Fisher’s exact test was used for statistical analysis. According to previous work, animals with persistent infection with	104 CFU/bladder
are characterized by the presence of latent quiescent reservoirs. (B) UPEC CFU in the bladder at 4 wpi. (C) UPEC CFU in the kidneys at 4 weeks following
monoinoculation with UPEC or coinoculation. For CFU analysis, n 3 to 8, at least 5 mice per experiment. The horizontal bar represents the median value for
each group ofmice. Statistical significance was determined by the two-tailedMann-Whitney test. *, P	 0.05; ***, P	 0.001. The dashed horizontal line indicates
the limit of detection of the assay. Titers below the limit of detection were assigned a value of 1 for visualization on the log scale and 0 for statistical analyses.
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posure of the urinary tract strongly influences the outcome of
persistent UPEC UTI.
DISCUSSION
Urinary tract infections are highly prevalent and afflict otherwise
healthy individuals across their life span, from infancy to old age.
Significant efforts have been made to understand the molecular
mechanisms underlying UTI, focusing largely on UPEC since it is
the uropathogen most frequently isolated from infected individ-
uals. The “gold standard” laboratory model in the field takes ad-
vantage of 7- to 8-week-old female mice transurethrally infected
with a single uropathogen. Studies using this model have revealed
novel aspects and mechanisms for UTI pathogenesis. However,
our understanding of the complexities associated with UTI sus-
ceptibility in at-risk groups and under more realistic infection
conditions is limited. The results presented here demonstrate that
GBS may be an underappreciated uropathogen, as it can shift
complex immunological responses in the urinary tract during
acute infection, altering UPEC-host interactions in ways that
change the long-term consequences of infection. These findings
call for further experimental and clinical studies to examine GBS,
as well as other common vaginal and gut bacteria, as potential risk
factors for UTI in susceptible groups, including pregnant, elderly,
and immunocompromised populations.
Our findings are consistent with coinfection studies at other
mucosal sites, bolstering the concept that bacterial community
members within the same niche are not blind to one another but
can interact inmutualistic and/or antagonistic ways (4, 45, 50). In
humans, clinical UTI is associated with increased sexual inter-
course frequency in the 14 days prior to diagnosis (8). It is likely
that polymicrobial UT exposure occurs prior to, or as a result of,
these events.When polymicrobial urine cultures are found in clin-
ically diagnosed UTI, the general clinical paradigm in healthy,
nonpregnant adults is that titers of Gram-positive bacteria of
	105 CFU/ml of urine are etiologically and clinically insignificant
in the background of a dominant UPEC infection. However, the
data presented here suggest that bacteria present at the time of
initial exposure can influence the outcome of UTI and still be at
low or undetectable levels by the time of UTI diagnosis. For these
reasons, we argue that the contribution of polymicrobial inocula-
tion to host UTI susceptibility has likely been underestimated.
Our findings call into question some long-held assumptions in the
field of clinical urology and urinary tract pathogenesis, showing
that the composition of a UT exposure can indeed influence the
cellular dynamics of host-uropathogen interactions and the out-
come of UTI.
Remarkably, GBS exerts effects on UPEC UTI despite its own
rapid clearance. While GBS did not measurably alter UPEC
invasion, exfoliation of epithelial cells (data not shown), or
recruitment of inflammatory cells (data not shown), its pres-
ence augmented early survival of UPEC in the bladder lumen.
This GBS-mediated augmentation of UPEC did not occur in
C3H/HeJ mice, which lack TLR4-driven responses, suggesting
that the influence of GBS on UTI outcomes may occur via GBS
modulation of host innate immune responses. Indeed, in vivo ex-
periments showed that GBS uses a capsule-mediated mechanism
to augment early titers of UPEC in the bladder lumen following
coexposure. In vitro experiments with murine macrophages fur-
ther demonstrated that the GBS capsule contributes to a state of
LPS tolerance via suppression of NF-B-driven responses. In this
way,GBS likely promotes the survival ofUPEC, andpossibly other
uropathogens, including otherwise unfit bacteria (such as UPEC
FimHmutants), in the acutely infected bladder. GBS suppression
of innate immune responses during acute UTI may, at optimal
doses, create amore hospitable environment for UPEC, leading to
the transcendence of early infection bottlenecks and alteration of
long-term infection (55).
Few bacterial species exist as monocultures in their native en-
vironments, and yet, the vast majority of microbiological studies
to date have been monomicrobial in nature. Recently, there has
been a growing appreciation for the significance of polymicrobial
infections as well as the importance of a healthy flora for resistance
to infection. Synergistic polymicrobial behavior has been impli-
cated in a variety of disease states, including sepsis (46), cystic
fibrosis lung infection (20, 51, 57, 58), community-acquired re-
spiratory infections (36, 37, 41), periodontal disease and other
oral pathogen infection models (44, 48), and UTI (7, 63). Our
increasing understanding of the complexity of infectious disease
states and the contribution of multiple etiologic agents under-
scores the need for modern genetic and molecular diagnostics
along with treatment tailored accordingly, a need especially im-
portant for chronic and recurrent diseases, such as UTI, that are
increasingly recalcitrant to treatment.
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